• <center id="my6c6"></center>
    <rt id="my6c6"><acronym id="my6c6"></acronym></rt>
  • <abbr id="my6c6"></abbr>
  •  

    上海強世信息科技有限公司

    Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.
    作者:Yoshihara K1, Gao Y, Shiga H, Wada DR, Hisaoka M. | 發(fā)布:Yuting Yang | 發(fā)布時間: 2018-09-10 | 1246 次瀏覽 | 分享到:
    Abstract

    BACKGROUND:
    Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype.

    OBJECTIVE:
    To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertensive patients, and to evaluate effects of covariates on the apparent oral clearance (CL/F), with particular emphasis on the effect of race.

    DESIGN:
    Retrospective analysis of data from 12 phase I-III trials in the US, Europe and Japan.

    PARTICIPANTS:
    Eighty-nine healthy volunteers and 383 hypertensive patients.

    METHODS:
    Nonlinear mixed-effects modelling was used to evaluate 7911 olmesartan plasma sample concentrations. The covariates included age, bodyweight, sex, race (Westerners [including Caucasians and Hispanics] versus Japanese), patient status (hypertensive patients versus healthy volunteers), serum creatinine level as an index of renal function and serum chemistry data as indices of hepatic function.

    RESULTS:
    The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6.66 L/h for a typical male Western hypertensive patient), absorption rate constant (1.46h-1), elimination rate constant (0.193h-1), rate constant from the central to peripheral compartment (0.061h-1), rate constant from the peripheral to central compartment (0.079h-1) and absorption lag-time (0.427h). Analysis of covariates showed that age, bodyweight, sex, patient status and renal function were factors influencing the clearance of olmesartan.

    CONCLUSION:
    The population pharmacokinetic analysis of olmesartan showed that: (i) severe renal impairment (serum creatinine >265 micromol/L [approximately 3 mg/dL]) could cause a clearance decrease of > or =30%; (ii) older age, lower bodyweight and being female were determinants of lower clearance but their effects on olmesartan clearance were within 20%; (iii) no statistically significant difference in clearance was found between Westerners and Japanese.
    99久久国产亚洲综合精品| 久久精品国产福利国产琪琪| 青青青国产成人久久111网站| 波多野结衣久久一区二区| 久久国产精品久久久久久| 国产精品99久久久久久猫咪| 国产香蕉久久精品综合网| 久久99精品国产免费观看| 免费精品久久天干天干| 国产综合久久久久鬼色| 国产精品久久久久久久久鸭| 久久久久亚洲AV成人无码网站| 久久久久久久久久久免费精品 | 久久综合精品国产一区二区三区 | 婷婷综合久久狠狠色99H| 一本久久a久久精品综合夜夜| 国内精品久久久久久久影视麻豆| 国产精品福利久久香蕉中文| 国产精品久久久久…| 色综合久久久久无码专区| 国产精品久久久久久吹潮| 久久人人爽人人精品视频| www国产亚洲精品久久久日本| 久久精品国内一区二区三区| 久久精品国产亚洲AV久| 99久久一香蕉国产线看观看| 久久久久久国产精品视频| 国产精品99久久免费观看| 狠狠色丁香久久婷婷综合| 久久青青草原亚洲av无码| 国产精品久久久久久久午夜片| 女人国产香蕉久久精品| 久久久久麻豆V国产精华液好用吗| 久久婷婷人人澡人人爽人人爱| 久久久无码人妻精品无码| 久久久久久久极品内射| 久久综久久美利坚合众国| 久久精品国产福利国产秒| 久久精品国产只有精品2020| 亚洲午夜久久久影院| 亚洲精品乱码久久久久久|